Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Merck
Express Scripts
Boehringer Ingelheim
Medtronic

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Roxadustat

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Roxadustat?

Roxadustat is an investigational drug.

There have been 20 clinical trials for Roxadustat. The most recent clinical trial was a Phase 1 trial, which was initiated on October 20th 2019.

The most common disease conditions in clinical trials are Anemia, Renal Insufficiency, Chronic, and Kidney Diseases. The leading clinical trial sponsors are FibroGen, Astellas Pharma Europe B.V., and AstraZeneca.

There are twenty-eight US patents protecting this investigational drug and one hundred and ninety-four international patents.

Recent Clinical Trials for Roxadustat
TitleSponsorPhase
Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis PatientsSecond Xiangya Hospital of Central South UniversityPhase 4
Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced AnemiaAstellas Pharma IncPhase 2
Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced AnemiaAstraZenecaPhase 2

See all Roxadustat clinical trials

Clinical Trial Summary for Roxadustat

Top disease conditions for Roxadustat
Top clinical trial sponsors for Roxadustat

See all Roxadustat clinical trials

US Patents for Roxadustat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Roxadustat   Start Trial Nitrogen-containing heteroaryl compounds and methods of use thereof FibroGen, Inc. (San Francisco, CA)   Start Trial
Roxadustat   Start Trial Crystalline forms of a prolyl hydroxylase inhibitor FibroGen, Inc. (San Francisco, CA)   Start Trial
Roxadustat   Start Trial Crystalline forms of a prolyl hydroxylase inhibitor FibroGen, Inc. (San Francisco, CA)   Start Trial
Roxadustat   Start Trial Nitrogen-containing heteroaryl compounds and methods of use thereof Fibrogen, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Roxadustat

Drugname Country Document Number Estimated Expiration Related US Patent
Roxadustat Austria 496033 2023-06-06   Start Trial
Roxadustat Australia 2004245552 2023-06-06   Start Trial
Roxadustat Brazil PI0411055 2023-06-06   Start Trial
Roxadustat Canada 2528232 2023-06-06   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Boehringer Ingelheim
Merck
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.